A small reset in fair value to €143.20, together with individual analyst targets moving to €135 from €150 and to €130 from €125, has put fresh focus on how Merck KGaA is being framed right now. These ...
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results